Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy

We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). We analyzed consecutive 42 eyes of 40 patients with treatment-naive nAMD associated with type 1 CNV. Three monthly injections of brolucizumab were completed in 36 eyes (85.7%). In those cases, best-corrected visual acuity (BCVA) was 0.24 +/- 0.27 at baseline and improved significantly to 0.12 +/- 0.23 after 3 months (P<0.001). Central macular thickness was 301110 mu m at baseline and decreased significantly to 160 +/- 49 mu m after 3 months (P<0.001). Dry macula was achieved in 34 eyes (94.4%) after the loading phase. Central choroidal thickness was 26489 mu m at baseline and decreased significantly to 223 +/- 81 mu m after 3 months (P<0.001). Indocyanine green angiography after the loading phase revealed complete regression of polypoidal lesions in 15 of the 19 eyes (78.9%) with polypoidal lesions. Non-infectious intraocular inflammation (IOI) was observed in 8 of 42 eyes (19.0%) during the loading phase, while showing amelioration in response to combination therapy with topical and subtenon injection of steroids. In these eyes, BCVA after 3 months had not deteriorated as compared to that at baseline. These results indicate that loading phase treatment with intravitreal brolucizumab might be effective for improving visual acuity and reducing exudative changes in eyes with nAMD associated with type 1 CNV. Moreover, polypoidal lesions appear to frequently regress after this treatment. However, we must monitor patients carefully for brolucizumab-related IOI, and administer steroid therapy promptly.

Automated summary

Loading phase treatment with intravitreal brolucizumab may improve visual acuity and reduce exudative changes in eyes with nAMD associated with type 1 CNV, but careful monitoring for brolucizumab-related intraocular inflammation is necessary.